Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Positive Ruling for Shionogi Now Final and Binding: Osaka Tax Suit
A Tokyo High Court decision rendered last month in favor of Shionogi has now become final and binding in a lawsuit over its tax payment linked to its joint venture with ViiV Healthcare, the Osaka drug maker said on May…
To read the full story
Related Article
- High Court Backs Positive Ruling for Shionogi in Osaka Tax Suit
April 16, 2021
- Osaka Tax Bureau Challenges Ruling on Shionogi Case
March 27, 2020
- Shionogi Wins Osaka Tax Suit over ViiV Deal
March 12, 2020
- Shionogi Takes Osaka Tax Bureau to Court
September 5, 2016
- Shionogi Says Complaint against ViiV-Related Tax Reassessment Rejected, Poised to Go to Court
March 30, 2016
- Shionogi Lodges Complaint against Tax Reassessment over ViiV Deal
November 12, 2014
- Shionogi Slapped with 1.3 Billion Yen in Back Taxes over ViiV Deal
September 17, 2014
BUSINESS
- Takeda Turns the Page to Kim’s “10-Year” Era, Betting on New Drugs and AI
June 26, 2026
- Sangamo Files Chapter 11, Astellas and Lilly Eye Key Assets
June 26, 2026
- Otsuka’s Centanafadine Meets PIII Goal in ADHD Patients with Anxiety
June 26, 2026
- Shionogi Welcomes Government Roadmap’s Focus on Infectious Diseases
June 26, 2026
- Sawai Cleared to Manufacture Nichi-Iko’s Lipitor Generic
June 26, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…